13D Filing: Sarissa Capital Management and Emmaus Life Sciences Inc.

Page 4 of 6 – SEC Filing

CUSIP No.  29137P109
Page 4 of 6 Pages
SCHEDULE 13D
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Sarissa Capital Offshore Master Fund LP
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)    ☐
(b)    ☐
3
SEC USE ONLY
4
SOURCE OF FUNDS

 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 ☐
6
CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER

497,657
8
SHARED VOTING POWER

 
9
SOLE DISPOSITIVE POWER

497,657
10
SHARED DISPOSITIVE POWER

 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

497,657
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:
 ☐
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.4%
14
TYPE OF REPORTING PERSON
 
PN

Follow Emmaus Life Sciences Inc.